RRR in Events - ComparisonDoes anyone have a comparison of the RRR (reletive risk reduction) of events (AKA: Mace) for RVX-208 vs. the PSCK9 inhibitors?
Yes, I know that RVX-208 is a "good cholesterol" drug (HDL) and the PSCK9 focus on "bad cholesterol" (LDL). And I also realize that MACE/events might be described/defined differently by different drug studies. Thus, there is an apples to oranges thing going on there.
But despite that isn't our MACE impact higher (across ALL of our patients) than that reported by the PSCK9 people??? (Not to mention our MACE reduction in the diabetes sub-population, which is higher still).....
And RVX-208 is an oral pill (vs. an injection), doesn't have the potential side-effect issues that the PSCK9 inhibitors do (cognitive issues, etc.), and is very low cost to product and administer.
Moreover: There's no argument the PSCK9 folks can make against RVX-208 in terms of our analysis having been post-hoc. Why? Because the PSCK9 information released is also post hoc.
Plus, I think the cost of doing our next trial is now much lower cost than the upcoming trials for the PSCK9 drugs. That has a big impact on valuation.
Doesn't all of this indicate that the true value of RVX-208 should be in excess of the valuations given to the PSCK9 drugs? Those drugs were valued in the billions....
Perhaps the comparison between the two classes of drugs is what has been driving the stock price of Resverlogix - and might also be driving discussions with pharma. Who knows, right?
I'm not saying that the PSCK9 drugs aren't valuable. And they focus on a different market of course - so I'm not saying that they are equivalents. Instead, what I am saying is that it looks to me like RVX-208 may be undervalued by the marketplace. Still. And by a large margin.
Just my opinion. DYODD. GLTA. IMHO.